论文部分内容阅读
本文报告我院1985年4月～9月收治的鼻咽癌患者112例．均为低分化鳞癌。随机分为综合组（放疗加化疗）和单纯放疗组，病例各56例．结果：鼻咽部和颈部肿块缩小情况．放疗剂量综合组达1906．09±1024.90cGy．肿瘤开始缩小．放疗剂量达5107．42±1825.99cGy时肿瘤开始消失．与单放组比较有差别（p＜0.05），完全缓解率：综合组为75％、单放组57.14％（p＜0.05）。5、10年生存率综合组分别为46.4％和14.3％．单放组为35.7％和10.7％，（p＜0.05）。复发或远处转移比较．综合组为39．3％.单放组为51.8％（p＞0.05）。资料提示；小剂量SHP在鼻咽癌治疗中起着一定的增敏或协同作用，对提高鼻咽癌生存率，减低复发和转移率有一定作用。
This article reports our hospital from April 1985 to September, 112 cases of patients with nasopharyngeal carcinoma. Poorly differentiated squamous cell carcinoma. Randomly divided into integrated group (radiotherapy and chemotherapy) and radiotherapy alone group, 56 cases of each. Results: Nasopharyngeal and neck mass shrinkage. Radiotherapy dose group reached 1906.09 ± 1024.90cGy. Tumor begins to shrink. At the dose of 5107.42 ± 1825.99cGy, the tumor began to disappear. Compared with the single group (p <0.05), the complete remission rate was 75% in the combined group and 57.14% in the single group (p <0.05). The overall 5-year and 10-year survival rates were 46.4% and 14.3% respectively. The single-arm group was 35.7% and 10.7%, respectively (p <0.05). Recurrence or distant metastasis comparison. The combined group was 39.3% and the single group was 51.8% (p> 0.05). Data suggest that low-dose SHP in nasopharyngeal carcinoma treatment plays a sensitizing or synergistic effect on improving the survival rate of nasopharyngeal carcinoma and reduce recurrence and metastasis rate has a certain effect.